Evolving chemotherapeutics

David Ranson presents at Ausbiotech I...

David Ranson presents at Ausbiotech Invest conference

David Ranson presented the Deflexifol opportunity at the recent Ausbiotech Invest and Partnering 2018 conference in Melbourne, Australia (http://ausbiotechinvestment.com.au/australia-biotech-invest/event-details)

Ground Zero Pharmaceuticals Inc to co...

Ground Zero Pharmaceuticals Inc to conduct regulatory review

FivepHusion has engaged Ground Zero Pharmaceuticals (https://groundzerous.com/) to conduct a strategic review of our phase 1 clinical trial results for Deflexifol, with a view to approaching the FDA for an IND application.

Bio-Link to assist FivepHusion with B...

Bio-Link to assist FivepHusion with Business Development

FivepHusion have engaged Bio-Link Australia to assist with business development and out-licensing opportunities for Deflexifol. Bio-Link (http://bio-link.com/) is a strategic consulting and biotechnology business development company that works with Australian and international life sciences companies and academic institutions to facilitate deals based on strategic technology analysis and consulting, business development, project management and deal negotiation.

ASCO 2017 – Detailed clinical t...

ASCO 2017 – Detailed clinical trial results presented

The phase 1 trial results were presented in greater detail in two posters at ASCO 2017 in Chicago this week. Professor Phil Clingan presented a poster: Deflexifol (a novel formulation of 5FU) Phase 1 Dose Escalation Study of Infusional or Bolus Schedules After Failure of Standard Treatment Clingan P. et al J Clin Oncol 35, 2017 […]

David Ranson to join Ausbiotech’...

David Ranson to join Ausbiotech’s Asian Investment Series in March 2017

David Ranson will be presenting the Deflexifol opportunity to potential investors in Singapore, Hong Kong and Shanghai as part of AusBiotech’s Asian Investment Series, March 21 – 28, 2017. See http://ausbiotechinvestment.com.au/ for more details.

Trial results presented at ASCO GI, 2...

Trial results presented at ASCO GI, 2017

A poster presentation by Professor Phil Clingan summarizing phase 1 results has been presented at the ASCO GI conference, San Francisco, January 19-21, 2017. J Clin Oncol 35, 2017 (suppl 4S; abstract TPS812)  

Deflexifol is safer for patients

Deflexifol is safer for patients

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Click to read this article.

Potent, with fewer side effects

Potent, with fewer side effects

Deflexifol (formerly Fluorodex) maintains in-vitro potency, overcomes incompatibility of 5-fluorouracil and folinic acid and may reduce phlebitis, catheter blockages and thromboembolic events. Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Read our article signalling improved patient outcomes from Deflexifol.

New hope for patients

New hope for patients

New hope being offered by Deflexifol to chemotherapy patients. Read here about new hope for chemotherapy patients.

New way to use an older drug

New way to use an older drug

Deflexifol is a new way of using an older drug. Read more.